TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has type 2 diabetes mellitus~* Males~* Females who are highly unlikely to become pregnant~* Participants poorly controlled without taking any, or taking one or two oral antidiabetic medications~Exclusion Criteria:~* Participant has a history of type 1 diabetes mellitus or history of ketoacidosis~* Participant required insulin therapy within the prior 8 weeks~* Participant is on or has been taking TZDs such as Actos® (pioglitazone) or Avandia® (rosiglitazone) within the prior 12 weeks of the screening visit

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- sitagliptin (Type: EXPERIMENTAL): Participants randomized to this arm will be administered sitagliptin 100mg daily, for six weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this arm will be administered matching placebo, daily for six weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytologically confirmed small cell lung cancer;~* Systemic chemotherapy that has previously received at least one or more lines regimen, followed by disease progression or recurrence;~* Age 18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months~* participants had at least one measurable target lesion by RECIST1.1~* The main organ function meets the following criteria:absolute value of neutrophils ≥ 1.5 × 109 / L, platelets ≥80 × 109 / L, hemoglobin ≥ 80 g / L;total bilirubin ≤ 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal value (if liver metastasis, ≤ upper limit of normal value 5 times), serum creatinine ≤ 1.5 times the upper limit of normal;~* Patients should participate in the study voluntarily and sign informed consent~Exclusion Criteria:~* Patients who have been used anti-angiogenesis inhibitors,such as (such as sunitinib,bevacizumab,endostar et al.~* Subjects with symptomatic brain metastases;~* Patients whose primary lesion with active bleeding within 4 months~* Hypertension, which is uncontrolled by the drug, is defined as: systolic blood pressure ≥ 160 mmHg, or diastolic blood pressure ≥ 100 mmHg~* Patients with active or unable to control serious infections~* Patients who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- S1/Anlotinib (Type: EXPERIMENTAL): Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Eligible patients had to have a 12-lead electrocardiogram (ECG) showing atrial fibrillation or atrial flutter with a ventricular rate of greater than or equal to 120 beats per minute and a systolic blood pressure of greater than or equal to 90 mmHg.~Exclusion Criteria:~Patients were excluded if they had any of the following:~* a systolic blood pressure \<90 mmHg, ventricular rate greater than or equal to 220 beats per minute,~* QRS \>0.100 seconds, 2nd or 3rd degree atrioventricular (AV) block,~* temperature \>38.0 ˚C,~* acute ST elevation myocardial infarction,~* known history of New York Heart Association Class IV heart failure or~* active wheezing with a history of bronchial asthma or COPD.~In addition, patients were excluded if there was:~* prehospital administration of diltiazem or any other AV nodal blockading agent,~* a history of cocaine or methamphetamine use in the previous 24 hours prior to arrival,~* a history of allergic reaction to diltiazem or metoprolol,~* a history of sick sinus or pre-excitation syndromes,~* a history of anemia with hemoglobin \<11.0 g/dl,~* pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metoprolol Study Group (Type: ACTIVE_COMPARATOR): Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)
- Diltiazem Study Group (Type: ACTIVE_COMPARATOR): Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Remifentanil and Remifentanil-Alfentanil Administration in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* children who were scheduled to undergo ophthalmic surgery under general anesthesia~Exclusion Criteria:~* developmental delay, neurologic or psychologic disease,~* history of sleep apnea,~* or history of general anesthesia

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane (Type: PLACEBO_COMPARATOR): Anesthesia was maintained with sevoflurane,and the incidence and severity of emergence agitation was investigated.
- Remifentanil (Type: ACTIVE_COMPARATOR): Anesthesia was maintained with sevoflurane and remifentanil. The incidence and severity of emergence agitation was compared with sevoflurane group.
- Alfentanil (Type: ACTIVE_COMPARATOR): Anesthesia was maintained with sevoflurane and remifentanil, and alfentanil was administered 10 min before the end of surgery.~The incidence and severity of emergence agitation was compared with sevoflurane group.
- Thiopental (Type: OTHER): General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
- Rocuronium (Type: OTHER): General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* An informed consent document signed and dated by the subject~* Age 18 to 55 years, inclusive~* In good health with no history of major medical conditions~* A total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m\^2 and ≤ 30kg/m\^2~Exclusion Criteria:~* Pregnant or nursing females~* Acute or chronic medical illness~* Abnormal lung function~* Positive for human immunodeficiency virus (HIV), active hepatitis A, B or C test~* Nose or nasopharynx abnormalities~* Receipt of any investigational drug within 3 months prior to the planned date of viral challenge/first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- EDP-938 Arm A (Type: EXPERIMENTAL): Subjects will take EDP-938 Dose 1 oral suspension for 5 days
- EDP-938 Arm B (Type: EXPERIMENTAL): Subjects will take EDP-938 Dose 2 oral suspension for 5 days
- Placebo Arm C (Type: PLACEBO_COMPARATOR): Subjects will take matching placebo oral suspension for 5 days
- EDP-938 Arm D (Type: EXPERIMENTAL): Subjects will take EDP-938 Dose 3 oral suspension for 5 days
- EDP-938 Arm E (Type: EXPERIMENTAL): Subjects will take EDP-938 Dose 4 oral suspension for 5 days
- Placebo Arm F (Type: PLACEBO_COMPARATOR): Subjects will take matching placebo oral suspension for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with clinical picture of oropharyngeal candidiasis~* Confirmation of oropharyngeal candidiasis by candida culture positive~* HIV-positive patients~* Patients 18 years of age~Exclusion Criteria:~* Patients with signs or symptoms of systemic candidiasis~* Patients with signs or symptoms of esophagitis~* Pregnant or breast-feeding women~* Patients who have taken systemic antifungals within the past 30 days~* Patients who have taken local antifungals within the past 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clotrimazole (Type: ACTIVE_COMPARATOR): Clotrimazole troches, 10 mg, 5 times per day for 14 days
- miconazole Lauriad (Type: EXPERIMENTAL): Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed diagnosis of chronic phase CML within last 3 months~* Patients with cytogenetically confirmed Ph positive CML in early chronic phase~Exclusion Criteria:~* Patients with Philadelphia chromosome negative but BCR-ABL positive CML~* Patients who used imatinib for 8 days or longer before study entry~* Patients who had been treated with other targeted anti-cancer therapy, except for Hydrea or Agrylin, which inhibits the growth of leukemic cells~* Patients with impaired cardiac function~* Cytologically confirmed CNS involvement~* Severe or uncontrolled chronic medical condition~* Other significant congenital or acquired bleeding disorders that are not related to underlying leukemia~* Patients who had a major surgery within 4 weeks prior to study entry or has not recovered from side effects of such surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: ACTIVE_COMPARATOR): Imatinib 400mg QD
- Radotinib 600mg (Type: EXPERIMENTAL): Radotinib 300mg BID
- Radotinib 800mg (Type: EXPERIMENTAL): Radotinib 400mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 to 65 years;~* A diagnosis of generalized anxiety disorder;~* Absence of current episode of major depression.~Exclusion Criteria:~* The presence or history of schizophrenia and other psychotic disorders;~* Hypertension;~* A current diagnosis of cancer, unless in remission for at least 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Combined With Bupivacaine for Erector Spinae Plane Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* elective posterior lumbosacral spine fixation and fusion surgery due to different causes that diagnosed clinically and radiologically including MRI and Plain X ray~Exclusion Criteria:~* hypersensitivity to the drugs used in the study \[local anesthetics, non-steroidal anti-inflammatory drugs, opioids and the drug under investigation (dexmedetomidine)\]~* patients with any contraindication to regional anesthesia as skin infections at the site of the block~* history of bleeding disorders or receiving anticoagulant medications

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine combined with bupivacaine group (DB group) (Type: ACTIVE_COMPARATOR): patients received 1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%,
- bupivacaine 0.25%, (Type: ACTIVE_COMPARATOR): patients received 20 ml of bupivacaine 0.25%
- control group (S group) (Type: PLACEBO_COMPARATOR): patients received 20 ml of normal saline 0.9%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cost-utility and Biological Underpinnings of MBSR in Fibromyalgia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
General Inclusion Criteria:~* Patients of both genders between 18-65 years old.~* Verified diagnosis of FMS according to the American College of Rheumatology criteria (ACR 1990).~* Ability to understand Spanish language.~* Written informed consent.~General Exclusion Criteria:~* Participation in other clinical trials~* Cognitive impairment according to MINI (total score ≤ 24)~* Receiving psychological treatment during the last or the current year~* Previous experience with meditation or mind-body therapies.~* Physical/psychiatric comorbidity that interferes with treatment (any severe medical illness, psychotic symptoms, substance abuse).~* Not being able to attend to group sessions.~* Being involved in ongoing litigation relating to the FMS.~Additional Inclusion Criteria for the biomarkers sub-study (90 participants in total):~* Female gender~* Right-handed~Additional Exclusion Criteria for the biomarkers sub-study:~* Neoplastic illnesses (diagnosed from the medical history), infection, cardiopulmonary, vascular or other internal medical conditions~* Use of oral or local corticosteroids or anti-cytokine therapy~* Needle-phobia~* Impossibility of being scanned in MRI (due to agoraphobia, metal implants, pace-marker...)~* BMI\> 36kg/m2 or \>110Kg~* Consuming \> 8 caffeine units per day~* Smoking \> 5 cigarettes per day~* Acute pain not related to the FMS at the day of biomarkers evaluation~* Being pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Mindfulness-Based Stress Reduction (Type: EXPERIMENTAL): Mindfulness-Based Stress Reduction (MBSR) The MBSR consists in eight 2-h group sessions and an all-day mindfulness retreat, and offers intensive and structured training in mindfulness meditation to help patients to relate to their physical and psychological conditions in more accepting and nonjudgmental ways. Participants will be encouraged to engage in home mindfulness practices. Sessions will be lead by 4 MBSR accredited instructors.
- Psycho-educational Program (Type: ACTIVE_COMPARATOR): Psycho-educational Program (FibroQol) It consists of eight 2-h group sessions including information about FMS (4 sessions) based on a consensus document of the Health Department of Catalonia + autogenic relaxation (4 sessions).
- Treatment As Usual (Type: OTHER): Treatment As Usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ethiopia Antimalarial in Vivo Efficacy Study 2012

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Slide-confirmed infection with P. vivax~* Age \> 1 year~* Lives within 20 km of the enrolling health facility~* Weight ≥ 5.0 kg~* Axillary temperature ≥ 37.5º C or history of fever during the previous 48 hours~* Patient or caregiver agrees to all finger pricks and return visits.~Exclusion Criteria:~* General danger signs or symptoms of severe malaria (see Annex II)~* Signs or symptoms of severe malnutrition, defined as weight-for-age ≤ 3 standard deviations below the mean (NCHS/WHO normalized reference values)~* Slide confirmed infection with any other Plasmodium species. besides P. vivax mono-infection~* Acute anemia, defined as Hg \< 8 g/dl~* Known hypersensitivity to any of the drugs being evaluated~* Presence of febrile conditions caused by diseases other than malaria~* Serious or chronic medical condition by history (cardiac, renal, hepatic diseases, sickle cell disease, HIV/AIDS)~* Pregnant or breastfeeding women.~* History or hemolysis or severe anemia~* Regular medication, which may interfere with antimalarial pharmacokinetics

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artemether-lumefantrine (Type: ACTIVE_COMPARATOR): Weight-based dose to be administered as fixed-dose combination twice daily for three days.
- Artemether-lumefantrine and primaquine (Type: EXPERIMENTAL): Artemether-lumefantrine will be given in a weight-based dose to be administered as fixed-dose combination twice daily for three days.~Primaquine will be given beginning on day 2 of artemether-lumefantrine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days.
- Chloroquine (Type: ACTIVE_COMPARATOR): Chloroquine will be given in a weight-based dose to be administered once daily for three days.
- Chloroquine and primaquine (Type: EXPERIMENTAL): Chloroquine will be given in a weight-based dose to be administered once daily for three days.~Primaquine will be given beginning on day 2 of chloroquine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety of Treatment of Articular Cartilage Lesions With CartiLife®

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 19 years old~* Defect size: 2 to 10 ㎠ on the unilateral knee cartilage (up to 4 ㎤ in volume)~* Defect: isolated ICRS (International Cartilage Repair Society) grade III or IV single defect chondral lesion on articular cartilage~* The joint space is maintained over 50% relative to baseline~* Patients that are able to walk without aid~* Patients that agree to abide by strict rehabilitation protocols and follow-up programs~* Patients who provide written consent to the participation of the clinical trial~Exclusion Criteria:~* Patients with inflammatory articular diseases such as rheumatoid arthritis or gouty arthritis~* Patients with arthritis associated with autoimmune disease~* Patients hypersensitive to bovine protein~* Patients with Haemophilia or markedly reduced immune function~* Patients hypersensitive to antibiotics such as gentamicin~* Patients with arterial bleeding and severe venous bleeding~* Patients with other diseases including tumors except for cartilaginous defects of joints~* Patients with a history of radiation treatment and chemotherapy within the past two years~* Patients who are pregnant, nursing a baby or likely to get pregnant~* Patients who participate in concurrent clinical trials or previous clinical trials within 30 days of administration~* Other cases where the investigator deems the patient ineligible for participation

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CartiLife (low-dose group) (Type: EXPERIMENTAL): Total defect volume in low-dose group is less than 2 ㎤. Low- and high-dose group are sequentially processed.
- CartiLife (high-dose group) (Type: EXPERIMENTAL): Total defect volume in High-dose group is 2 \~ 4 ㎤.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Individualized vs. Household MRSA Decolonization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals who are enrolled in a 12-month observational study entitled The Community-Associated Methicillin-Resistant Staphylococcus aureus Among Household Members and the Home Environment Study.~Exclusion Criteria:~* Households in which all members experienced SSTI during the 12-month observational study~* Individuals with known allergies to mupirocin or bleach (sodium hypochlorite)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Individualized Approach (Type: ACTIVE_COMPARATOR): The decolonization regimen will be performed only by those household members who experienced SSTI in the prior year.
- Household Approach (Type: ACTIVE_COMPARATOR): All members of the household will perform the decolonization regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete